Biomind Labs Inc. (CSE: BMND; OTC Pink: BMNDF), a Vancouver-based clinical-stage biopharmaceutical company developing central nervous system therapies, began trading on the Canadian Securities Exchange on August 11 under the symbol BMND. Its common shares were previously listed on Cboe Canada, where they were delisted at the close of trading on August 10.
Biomind said shareholders did not need to take action and its OTC Pink listing was unaffected. The CSE issuer profile lists 77,571,773 common shares issued and outstanding and 6.2 million shares reserved for issuance. The exchange transfer did not itself raise capital, issue new shares or include new clinical results.
The CSE announcement described Biomind as developing fast-acting and controlled-release drugs and tailored delivery systems for psychiatric and neurological conditions. It said the company had four products in either Phase 1 or Phase 2 clinical trials.
“The CSE’s entrepreneurial focus and commitment to emerging biotechnology companies make it a natural market for our next stage of growth,” Biomind CEO Alejandro Antalich said.
Biomind’s latest management’s discussion and analysis provides important context on the pipeline. The filing states that the phase labels may refer to investigational new drug clinical trials rather than commercial clinical trials. It reports that BMND01 completed a Phase 1/2a investigational trial and BMND08 completed Phase 1/2a work, but further trials for both candidates are currently on hold. Preclinical work for BMND06 was completed, while its proposed Phase 1 and Phase 2a studies are also on hold.
The company said it has insufficient working capital to proceed with further trials and that programs intended to move its projects toward commercialization are principally on hold while it seeks funding. If financing becomes available, Biomind plans to prioritize BMND08, a 5-MeO-DMT-based candidate, followed by BMND01, a DMT-based candidate for treatment-resistant depression.
As of March 31, 2026, Biomind reported US$14,387 in cash, US$1.83 million in current liabilities and a US$1.81 million working-capital deficit. It recorded no revenue and a US$104,101 net loss for the quarter. The company assessed its liquidity risk as high and said it remains dependent on external financing. The CSE listing does not, by itself, resolve those funding needs.
Investors also have a disclosure-compliance history to consider. The Ontario Securities Commission revoked a failure-to-file cease trade order against Biomind on November 25, 2025. The order is no longer in effect.
Upcoming Catalysts
- Financing: Any capital raise or other funding sufficient to restart clinical development.
- Pipeline: Updates on the planned advancement of BMND08 and, subsequently, BMND01.
- Regulatory: FDA-directed development updates for BMND08, including any progress on trial design, manufacturing scale-up or an expedited regulatory pathway. Biomind has not provided a firm timetable for these steps.
Sources
- Canadian Securities Exchange welcomes Biomind Labs listing, August 11, 2026 — Newsfile Corp.
- Biomind Labs announces CSE listing and Cboe Canada delisting, August 6, 2026 — ACCESS Newswire
- Biomind Labs Inc. issuer profile — Canadian Securities Exchange
- Biomind management’s discussion and analysis for the three months ended March 31, 2026 — SEDAR filing mirror
- Biomind Labs cease trade order revocation, November 25, 2025 — Ontario Securities Commission
Editorial Disclosure
This article is based entirely on publicly available information, including press releases, SEDAR filings and publicly available regulatory and exchange sources. Securities discussed or referenced include Biomind Labs Inc. (CSE: BMND; OTC Pink: BMNDF). Biotech Stocks Daily has not received any compensation from any company mentioned, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which does not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used were the Canadian Securities Exchange’s August 11, 2026 announcement distributed through Newsfile Corp.; Biomind Labs’ August 6, 2026 announcement distributed through ACCESS Newswire; the Canadian Securities Exchange issuer profile accessed August 12, 2026; Biomind’s management’s discussion and analysis for the three months ended March 31, 2026; and the Ontario Securities Commission’s November 25, 2025 cease trade order revocation.
As of March 31, 2026, Biomind reported US$14,387 in cash, US$1.83 million in current liabilities, a US$1.81 million working-capital deficit, no revenue and a US$104,101 quarterly net loss. The company assessed its liquidity risk as high and stated that it remains dependent on external financing. Its filing said it had insufficient working capital to proceed with further trials and that programs intended to advance its projects toward commercialization were principally on hold while it sought funding. Failure to obtain financing could reduce the scope of operations and further dilute shareholders if equity is issued.
The August 2026 CSE listing was a transfer from Cboe Canada. It did not itself raise capital, issue new shares or announce new clinical data. Biomind previously faced a failure-to-file cease trade order that the Ontario Securities Commission revoked on November 25, 2025. The order is no longer in effect.
Financial and share-count information reflects the dates stated above and may change. No market-price data was used in this article. Readers should verify current filings and market information before making decisions.
These are speculative investments carrying significant risk, including potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information, please see our full DISCLAIMER.
